PLUS1
11.96
1.18 (10.95%)
1.18 (10.95%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| BioCryst Pharmaceuticals Inc | BCRX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 1.18 | 10.95% | 11.96 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 11.27 | 11.20 | 12.08 | 11.98 | 10.78 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 11.89 | 11.98 | 0.09 | 1 | - |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 29,944 | 5,784,571 | $ 11.74 | $ 67,915,584 | 6,668,239 | 1.58 - 12.90 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:59:51 | formt | 159 | $ 11.96 | USD |
BioCryst Pharmaceuticals Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 2.11B | 176.57M | 164.27M | $ 48.84M | $ - | -0.94 | -12.80 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
BioCryst Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 3/01/2021 | 16:41 | Edgar (US Regulatory) | Automatic Shelf Registration Statement of Securities of.. |
| 2/25/2021 | 16:40 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 2/25/2021 | 16:26 | Seeking Alpha | BioCryst's ORLADEYO nabs CHMP positive recommendation in.. |
| 2/25/2021 | 16:15 | GlobeNewswire Inc. | BioCryst Receives Positive CHMP Opinion for ORLADEYO™.. |
| 2/25/2021 | 07:11 | Seeking Alpha | BioCryst Pharmaceuticals EPS misses by $0.09, misses on.. |
| 2/25/2021 | 07:06 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 2/25/2021 | 07:00 | GlobeNewswire Inc. | BioCryst Reports Fourth Quarter and Full Year 2020 Financial.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BCRX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 11.69 | 12.41 | 10.29 | 11.06 | 7,032,272 | 0.27 | 2.31% |
| 1 Month | 10.75 | 12.90 | 8.86 | 10.72 | 9,528,823 | 1.21 | 11.26% |
| 3 Months | 6.82 | 12.90 | 6.46 | 9.20 | 7,916,497 | 5.14 | 75.37% |
| 6 Months | 4.21 | 12.90 | 3.30 | 6.93 | 6,583,018 | 7.75 | 184.09% |
| 1 Year | 3.08 | 12.90 | 1.58 | 5.18 | 7,720,173 | 8.88 | 288.31% |
| 3 Years | 4.95 | 12.90 | 1.38 | 4.91 | 3,566,015 | 7.01 | 141.62% |
| 5 Years | 2.01 | 12.90 | 1.38 | 4.97 | 2,640,167 | 9.95 | 495.02% |
BioCryst Pharmaceuticals Description
| BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology. |
